The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.
The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.
The purpose of this research study is to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating Ulcerative Colitis (UC).
The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.
PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.
The purpose of this study is to see if guselkumab and golimumab when used together is safe and effective for treating participants with moderately to severely active ulcerative colitis (UC).
Guselkumab has been approved in the USA, the European Union (EU), Canada, and several other countries, including the Australian health authority (Therapeutic Goods Administration), for the treatment of adult patients with moderate to severe plaque psoriasis. In addition, guselkumab is being studied for the treatment of psoriatic arthritis, Crohn’s disease, and paediatric psoriasis.
Golimumab has been approved in countries worldwide, including the Therepeutic Goods Administration, for the indications of moderately to severely active ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The primary purpose of your participation in this study is not to treat you for your condition but to help answer the following research question: How mirikizumab compares with placebo in helping patients with UC?
Mirikizumab is an experimental treatment. This means that it is not an approved treatment for UC in Australia, by the Therapeutic Goods Administration.
The ColoSTAT® test is being developed to provide an alternative option for people to undergo a colorectal cancer (CRC) screening test but for clinical, personal or cultural reasons, are unwilling or unable to use a stool test or are reluctant to undergo more invasive and costly procedures such as colonoscopy and sigmoidoscopy.
ColoSTAT® involves the collection of a blood sample, rather than stool, to assess the presence of components in the blood which, when assessed using a specifically designed algorithm, provide a CRC risk score. The algorithm uses the results from the blood test and incorporates other CRC risk factors, such as family history and lifestyle factors to determine this risk rating.
The purpose of this study is to assess a novel blood collection device, called a Plasma Separation Device (PSD), which has been developed at the Burnet Institute in Melbourne. The PSD is designed to collect and store blood samples in remote and resource-poor settings and to assist with infectious diseases testing. The study team want to measure the effectiveness of the PSD for the diagnosis of Hepatitis B, Hepatitis C and HIV. They also want to see if the PSD can detect other immune responses to infectious diseases that you have been vaccinated against (e.g. measles or tetanus).
The purpose of this research is to find out whether the study medication denosumab can help prevent breast cancer in women with a BRCA1 mutation. The research also aims to find out whether denosumab decreases the risk of developing ovarian cancer or other types of cancer, study the safety of using denosumab, and study its effect on bone health.
The study is a randomised, double-blind, placebo-controlled study. This means that participants will receive an injection of either denosumab or placebo (no drug) every 6 months for 5 years. Participants will need to visit their study doctor every 6 months while receiving the medication and will continue to be checked by their study team every 12 months for a further 5 years (total of 10 years).
Patients diagnosed with glioblastoma are treated with a combination of chemotherapy and radiation, followed by six months of temozolomide (chemotherapy). However, even with the best treatment, the average survival is around 14 months. Previous research has suggested that an extra six months of temozolomide may improve survival without any impact on quality of life or symptoms related to treatment. However, these studies were small and unable to provide a definitive answer. In some centres, it is standard to use six months of chemotherapy, whilst in others, the standard is 12 months.
The purpose of this study is to determine if an additional six months of temozolomide will improve the survival of patients with glioblastoma. We will also assess whether an additional six months of temozolomide causes more side effects.
Patients who decide to participate in the trial will be randomly assigned to either receive an additional six months of temozolomide chemotherapy or not and continue with their usual care.